Overview

Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in combination with nivolumab and ipilimumab for the treatment of ccRCC and potentially other solid tumor types.

Phase:

Phase 1

Details

Lead Sponsor:

Mirati Therapeutics Inc.

Treatments:

Ipilimumab
Nivolumab